UK court OKs Herceptin biosimilar

Share this article:

Biosimilar Herceptin is coming to the UK. Bloomberg reports that a London judge declared two of Roche's patents invalid.

Herceptin patents were set to expire in July but Bloomberg notes this lawsuit was over two additional patents that applied to dosing and composition.

Roche has been preparing for a Herceptin biosimilar for some time, including landing regulatory approval for breast cancer treatment Kadcyla.

Dubbed “super Herceptin,” this treatment combines blockbuster Herceptin with a taxane chemotherapy, as well as a third chemical developed by San Francisco-based ImmunoGen and licensed by Genentech that binds the medicines together.

Share this article:

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.